Walgreens sales momentum poised to improve, says BB&T After meeting with Walgreens CEO, BB&T believes that the company's revenue trends have begun to rebound. The firm expects the company to benefit from share gains in pharmaceuticals and increased promotions. It raised its price target on the stock to $59 from $53 and keeps a Buy rating on the shares.
News For WAG From The Last 14 Days
Check below for free stories on WAG the last two weeks.